Vitrum osteomag in prevention of osteoporosis inpostmenopausal women: results of the comparative openmulticenter trial


Aim. To investigate efficacy, tolerance and safety of the drug vitrum osteomag one tablet of which contains
600 mg calcium (1500 mg calcium carbonate), 200IU of cholecalcepherol, 40 mg of magnesium,
zinc (7.5 mg), copper (1 mg), manganese (1.8 mg) and boron (250 meg) in women with osteopenia for
prevention of osteoporosis
Material and methods. Л multicenter comparative open trial ofvitrum osteomag influence on mineral
bone density (MED), change of pain syndrome in bones, index of calcium-phosphorous metabolism
covered 334 postmenopausal women with osteopenia. MBD was measured in low-back spine and proximal
part of the hip with DEXA method. All the patients were divided into 3 groups: 125 women taking
2 tablets ofvitrum osteomag daily for 12 months (group 1); 111 women taking 1500 mg calcium carbonate
(group 2); 96 women - control group (only observation).
Results. Vitrum osteomag relieved pain in the back and joints, had a positive effect on bone density
(+1.5%) and proximal parts of the hip (0.6-0.93%) exceeding the effect of calcium carbonate only
which preserves the initial MBD in low back spine but does not prevent bone loss in the hip. MBD dynamics
in patients given vitrum osteomag differs essentially from one in the control group (from -1.9
to -2.91%) which demonstrates a reliable preventive anti-osteoporotic effect of this medication. The
drug increases the level of general and ionized calcium in blood but does not cause hypercalcemia
lowering the level of parathormone in blood. The rate of side effects in group 1 was 14,4% and did not
differ much from that in group 2 (16.2%).
Conclusion. The results of the study allow to recommend vitrum osteomag for prophylaxis of a rapid
loss of bone tissue mineral density.


  1. Беневоленская Л. И. Общие принципы профилактики и лечения остеопороза. Консилиум 2002; 2 (6): 240-244.
  2. Drown J. P., Josse R. G. Clinical practice guidelines for the diagnosis management of osteoporosis in Canada. Can. Med. Assoc. J. 2002; 12 (suppl. 10): 167.
  3. Дедух Н. В., Бенгус Л. М., Басти А. Магний и костная ткань (обзор литературы и собственные данные). Остеопороз и остеопатии 2003; 1: 18-22.
  4. Rude R. R. Magnezium deficiency; a possible risk factor for osteoporosis. In: Burckhard P., Dowson-Hughes В., Heaney R. P., eds. Nutritional aspects of osteoporosis. San Diego: Academic Press 2001. 263-271.
  5. Shea В., Wells G., et al. Calcium supplementation on bone loss in postmenopausal women. (Cochrane review). Cochrane Library 2004; 1.
  6. Conlan D. Korula R. Serum copper levels in elderly patients with femoral neek fractures. Age and Ageing 1990; 19: 212- 214.
  7. Орбелис Д. Новый подход к проблеме микроэлементов. Микроэлементы в мед. 2002; 3(1): 2-7.
  8. Aloia J. F., Vaswani A., Yen J. К. et al. Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. Ann. Intern. Med. 1994; 120: 97- 103.
  9. Торопцова Н. В., Беневоленская Л. И. Профилактика осгеопороза и переломов. В кн.: Руководство по остеопорозу. М.: Бином; 2003; гл. 16: 320-344.

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies